The financial markets are buzzing with fresh momentum as a landmark decision from U.S. regulators redefines the digital asset landscape. On January 11, 2024, the U.S. Securities and Exchange Commission (SEC) officially approved 11 spot Bitcoin exchange-traded funds (ETFs), marking a pivotal moment in the institutional adoption of cryptocurrencies. This development is sending ripples across global markets, including Hong Kong’s equity and futures trading arenas.
As investors recalibrate their strategies, Hong Kong-listed firms tied to blockchain and digital assets—such as BC Technology Group (00863), CSOP Bitcoin ETF (03066), and CSOP Ether ETF (03068)—are drawing renewed attention. Meanwhile, U.S. equities closed higher ahead of key inflation data, reflecting sustained investor confidence.
👉 Discover how the Bitcoin ETF approval is reshaping investment strategies in 2025.
Global Markets React to Regulatory Milestone
U.S. markets ended Wednesday on a positive note, with the Dow Jones Industrial Average closing at 37,695.73—an increase of 170.57 points. The S&P 500 rose by 26.95 to settle at 4,783.45, while the tech-heavy Nasdaq Composite gained 111.94 points, finishing at 14,969.65.
The rally comes amid market anticipation of the latest U.S. inflation figures, set for release on Thursday. However, the dominant narrative remains the SEC’s historic approval of spot Bitcoin ETFs, a move long awaited by institutional investors and crypto advocates alike.
This regulatory green light not only legitimizes Bitcoin as a tradable asset class within traditional finance but also opens the door for broader retail and institutional participation through familiar investment vehicles like ETFs.
Hong Kong Market Indicators
In after-hours trading, the Hang Seng Index futures closed at 16,150 points—down 4 points but still showing a premium of 53 points over the previous day’s cash market close—with a total volume of 11,851 contracts traded. The slight dip suggests cautious positioning ahead of major earnings releases and macroeconomic updates.
Despite sector-specific headwinds, several Hong Kong-listed stocks are showing resilience and growth potential across biotech, electric vehicles, and consumer retail sectors.
Key Corporate Updates
WuXi Biologics (02269)
The company is set to present at the 42nd Annual J.P. Morgan Healthcare Conference today. The presentation will cover updates on business operations and strategic initiatives, offering investors valuable insights into its global R&D pipeline and manufacturing capabilities.
Li Auto (02015)
Li Auto announced robust delivery figures for 2023, with a total of approximately 376,000 vehicles delivered—an impressive milestone that underscores growing consumer demand for premium electric SUVs in China. Notably, monthly deliveries surpassed 50,000 units, with the Ideal L7 model alone exceeding 20,000 units per month.
This performance positions Li Auto as a leading player in China’s competitive new energy vehicle (NEV) market.
Hong Kong Exchanges and Clearing (HKEX) (00388)
HKEX has signed a memorandum of understanding with the Xi’an municipal government to strengthen cooperation and support Xi’an-based enterprises in listing on the Hong Kong Stock Exchange. This collaboration highlights HKEX’s ongoing efforts to deepen ties with mainland innovation hubs and expand its pipeline of high-growth tech listings.
Lenovo (00992)
At the 2024 Consumer Electronics Show (CES), Lenovo unveiled over 40 new AI-powered devices and solutions across its Yoga, ThinkBook, ThinkPad, ThinkCentre, and Legion product lines. Among these are more than ten new AI PCs designed to enhance productivity through on-device artificial intelligence.
This strategic push underscores Lenovo’s commitment to leading the next wave of computing innovation driven by generative AI and edge processing.
Yue Yuen Industrial (Holdings) (00551)
The footwear manufacturing giant reported full-year consolidated operating revenue of USD 7.89 billion—a 12% decline year-on-year—reflecting ongoing challenges in global consumer demand and supply chain dynamics.
Junshi Biosciences (01877)
The biopharmaceutical firm received formal notice from Coherus BioSciences regarding the termination of the licensing agreement for JS006, a recombinant humanized anti-TIGIT monoclonal antibody. The termination will take effect six months after receipt of the notice, allowing time for transition planning.
While this development may impact future collaboration revenue, Junshi retains full rights to advance JS006 independently in Greater China.
Yuzhou Group (01628)
The property developer recorded RMB 17.836 billion in cumulative contracted sales for the year—a 49.91% drop from the prior year—on a sales area of 1.0881 million square meters (down 46.04%). The average selling price stood at RMB 16,396 per square meter.
These figures reflect continued pressure in China’s real estate sector amid prolonged market adjustments.
Sa Sa International (00178)
For the third quarter ended December 31, 2023, Sa Sa reported a 36.7% year-on-year increase in turnover to HKD 1.182 billion. Offline sales rose 35.7% to HKD 951 million, while online sales surged 41.2% to HKD 232 million—demonstrating strong recovery in both channels post-pandemic.
👉 Explore how digital transformation is boosting retail stock performance in Asia.
Shimao Group (00813)
Shimao posted annual contracted sales of approximately RMB 42.82 billion—down 50.51% year-over-year—on a contracted sales area of 2.9466 million square meters (a 45.17% decrease). The results highlight ongoing liquidity constraints and weak buyer sentiment in China's property market.
Pou Sheng International (03813)
In contrast, Pou Sheng International reported a solid performance with full-year consolidated operating revenue reaching RMB 20.064 billion—an increase of 7.7% compared to the previous year—signaling resilient consumer demand for sportswear and athletic footwear.
Frequently Asked Questions (FAQ)
Q: What does the approval of spot Bitcoin ETFs mean for investors?
A: It allows traditional investors to gain exposure to Bitcoin’s price movements without holding the actual cryptocurrency, reducing custody risks and increasing accessibility through regulated brokerage accounts.
Q: Which Hong Kong stocks could benefit from the Bitcoin ETF approval?
A: Companies like BC Technology Group (00863) and asset managers offering crypto-linked ETFs such as CSOP (03066, 03068) may see increased trading volumes and investor interest due to heightened market sentiment around digital assets.
Q: How might AI-driven devices impact tech stocks like Lenovo?
A: By launching AI PCs and smart solutions, Lenovo is positioning itself at the forefront of the AI revolution in personal computing, potentially driving long-term revenue growth and market share gains.
Q: Is the Chinese property sector stabilizing?
A: Current data from developers like Yuzhou and Shimao suggest continued contraction, though policy support from Beijing may gradually improve conditions in select regions over 2025.
Q: Why did Junshi Biosciences lose its licensing deal with Coherus?
A: Specific reasons were not disclosed, but such decisions often stem from shifting strategic priorities or clinical trial outcomes. Junshi now has full control over JS006 development in China.
Q: Are consumer brands like Sa Sa recovering post-pandemic?
A: Yes—Sa Sa’s strong double-digit sales growth in both online and offline channels indicates a meaningful rebound in discretionary spending and foot traffic in Hong Kong and mainland China.
Final Outlook
The approval of spot Bitcoin ETFs represents more than just a regulatory shift—it's a structural evolution in how financial markets view digital assets. For Hong Kong investors, this opens new avenues for portfolio diversification while spotlighting local firms positioned at the intersection of finance and technology.
Meanwhile, earnings updates from key sectors—from EVs to biotech—paint a mixed but telling picture of economic resilience amid global uncertainties.
👉 Stay ahead of market trends with real-time insights from top financial platforms.
Core keywords naturally integrated throughout: Bitcoin ETF approval, Hong Kong stock analysis, spot Bitcoin ETF, SEC approval, crypto investment, Hang Seng Index futures, U.S. inflation data, AI PC innovation.